Coherus BioSciences Inc/ US19249H1032 /
2024-05-10 4:18:20 PM | Chg. -0.2350 | Volume | Bid4:19:01 PM | Ask4:19:01 PM | High | Low |
---|---|---|---|---|---|---|
1.8850USD | -11.08% | 2.14 mill. Turnover: 3.92 mill. |
1.8900Bid Size: 100 | 1.9000Ask Size: 1,200 | 2.1800 | 1.8300 |
GlobeNewswire
05-09
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
04-24
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
04-08
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...
GlobeNewswire
03-13
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Bu...
GlobeNewswire
03-05
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
GlobeNewswire
03-04
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire
02-21
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery S...
GlobeNewswire
02-21
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
GlobeNewswire
01-22
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All ...
GlobeNewswire
01-22
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire
01-18
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Ant...
GlobeNewswire
01-03
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
01-03
Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief...
GlobeNewswire
2023-12-26
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery...